Visceral leishmaniasis: What are the needs for diagnosis, treatment and control?

Nature Reviews Microbiology

Volumn 5, Issue 11, 2007, Pages 873-882

  Chappuis, François ^a,b   Sundar, Shyam ^c   Hailu, Asrat ^d   Ghalib, Hashim ^e   Rijal, Suman ^f   Peeling, Rosanna W ^e   Alvar, Jorge ^e   Boelaert, Marleen ^g  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Swiss Section   (Switzerland)

^c BANARAS HINDU UNIVERSITY   (India)

^d ADDIS ABABA UNIVERSITY   (Ethiopia)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^g Prince Leopold Institute of Tropical Medicine   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; LEISHMANIA VACCINE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; SITAMAQUINE; STIBOGLUCONATE SODIUM; ALANINE AMINOTRANSFERASE; ANTIGEN; ASPARTATE AMINOTRANSFERASE; BCG VACCINE; CREATININE; DELTAMETHRIN; INSECTICIDE; PROTOZOON ANTIBODY; PROTOZOON ANTIGEN; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST OF ILLNESS; CREATININE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EARLY INTERVENTION; FEVER; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; INFECTION CONTROL; INJECTION SITE PAIN; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PATHOGENESIS; PHLEBOTOMUS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RIGOR; RISK FACTOR; SIDE EFFECT; VISCERAL LEISHMANIASIS; AFRICA; ANTIBODY DETECTION; ANTIGEN DETECTION; BED NET; COST EFFECTIVENESS ANALYSIS; DRUG FEVER; DRUG PREFERENCE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; MORBIDITY; PARASITE IDENTIFICATION; PATIENT COMPLIANCE; PSYCHODIDAE; PUBLIC HEALTH; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION; VECTOR CONTROL;

ANIMALS; ANTIPROTOZOAL AGENTS; COMMUNICABLE DISEASE CONTROL; DRUG THERAPY, COMBINATION; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL;

PHLEBOTOMINAE; PROTOZOA;

EID: 35548987998     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro1748     Document Type: Review

References (168)

1. Herwaldt, B. L. Leishmaniasis. Lancet 354, 1191-1199 (1999).
2. Pearson, R. D. & Sousa, A. Q. Clinical spectrum of Leishmaniasis. Clin. Infect. Dis. 22, 1-13 (1996).
3. Arevalo, J. et al. Influence of leishmania (viannia) species on the response to antimonial treatment in patients with american tegumentary leishmaniasis. J. Infect. Dis. 195, 1846-1851 (2007).
4. Dedet, J. P. & Prationg, F. in Manson's Tropical Diseases (eds Cook, G. C. & Zumla, A. I.) 1339-1364 (Elsevier, London, 2003).
5. Lukes, J. et al. Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc. Natl Acad. Sci. USA 104, 9375-9380 (2007).
6. Mauricio, I. L., Stothard, J. R. & Miles, M. A. The strange case of Leishmania chagasi. Parasitol. Today 16, 188-189 (2000).
7. Alvar, J., Canavate, C., Molina, R., Moreno, J. & Nieto, J. Canine leishmaniasis. Adv. Parasitol. 57, 1-88 (2004).
8. Zijlstra, E. E., Musa, A. M., Khalil, E. A., el-Hassan, I. M. & el-Hassan, A. M. Post-kala-azar dermal leishmaniasis. Lancet Infect. Dis. 3, 87-98 (2003).
9. Addy, M. & Nandy, A. Ten years of kala-azar in west Bengal, Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull. World Health Organ. 70, 341-346 (1992).
10. Desjeux, P. Leishmaniasis: Current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27, 305-318 (2004).
11. WHO. The World Health Report [online] (WHO, Geneva, Switzerland, 2002).
12. Collin, S. M., Coleman, P. G., Ritmeijer, K. & Davidson, R. N. Unseen Kala-azar deaths in south Sudan (1999-2002). Trop. Med. Int. Health 11, 509-512 (2006).
13. Singh, S. P., Reddy, D. C., Rai. M. & Sundar, S. Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop. Med. Int. Health 11, 899-905 (2006).
14. Boelaert, M. et al. Visceral leishmaniasis control: A public health perspective. Trans. R. Soc. Trop. Med. Hyg. 94, 465-471 (2000).
15. Desjeux, P. The increase in risk factors for leishmaniasis worldwide. Trans. R. Soc. Trop. Med. Hyg. 95, 239-243 (2001)
16. Seaman, J., Mercer, A. J. & Sondorp, E. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: Course and impact from 1984 to 1994. Int. J. Epidemiol. 25, 862-871 (1996).
17. Alvar, J., Yactayo, S. & Bern, C. Leishmaniasis and poverty. Trends Parasitol. 22, 552-557 (2006).
18. Ahluwalia, I. B. et al. Visceral leishmaniasis: Consequences of a neglected disease in a Bangladeshi community. Am. J. Trop. Med. Hyg. 69, 624-628 (2003).
19. Rijal, S., Koirala, S., Van der Stuyft, P. & Boelaert, M. The economic burden of visceral leishmaniasis for households in Nepal. Trans. R. Soc. Trop. Med. Hyg. 100, 838-841 (2006).
20. Hotez, P. J. et al. Combating tropical infectious diseases: Report of the Disease Control Priorities in Developing Countries Project. Clin. Infect. Dis. 38, 871-878 (2004).
21. Siddig, M., Ghalib, H., Shillington, D. C., Petersen, E. A. & Khidir, S. Visceral leishmaniasis in Sudan. Clinical features. Trop. Geogr. Med. 42, 107-112 (1990).
22. Zijlstra, E. E. et al. Kala-azar in displaced people from southern Sudan: Epidemiological, clinical and therapeutic findings. Trans. R. Soc. Trop. Med. Hyg. 85, 365-369 (1991).
23. Rittig, M.G. & Bogdan, C. Leishmania - host-cell interaction: complexities and alternative views. Parasitol. Today 16, 292-297 (2000).
24. Lodge, R., Diallo, T.O. & Descoteaux, A. Leishmania donovani lipophosphoglycan blocks NADPH oxidase assembly at the phagosome membrane. Cell. Microbiol. 8, 1922-1931 (2006).
25. Khalil, E. A., Zijlstra, E. E., Kager, P. A. & El Hassan, A. M. Epidemiology and clinical manifestations of Leishmania donovani infection in two villages in an endemic area in eastern Sudan. Trop. Med. Int. Health 7, 35-44 (2002).
26. Zijlstra, E. E., el-Hassan, A. M., Ismael, A. & Ghalib, H. W. Endemic kala-azar in eastern Sudan: A longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am. J. Trop. Med. Hyg. 51, 826-836 (1994).
27. Schaefer, K. U., Kurtzhals, J. A., Gachihi, G. S., Muller, A. S. & Kager, P. A. A prospective seroepidemiological study of visceral leishmaniasis in Baringo District, Rift Valley Province, Kenya. Trans. R. Soc. Trop. Med. Hyg. 89, 471-475 (1995).
28. Ali, A. & Ashford, R. W. Visceral leishmaniasis in Ethiopia. IV. Prevalence, incidence and relation of infection to disease in an endemic area. Ann. Trop. Med. Parasitol. 88, 289-293 (1994).
29. Davies, C. R. & Mazloumi Gavgani, A. S. Age, acquired immunity and the risk of visceral leishmaniasis: A prospective study in Iran. Parasitology 119, 247-257 (1999).
30. Evans, T. G. et al. Epidemiology of visceral leishmaniasis in northeast Brazil. J. Infect. Dis. 166, 1124-1132 (1992).
31. Badaro, R. et al. New perspectives on a subclinical form of visceral leishmaniasis. J. Infect. Dis. 154, 1003-1011 (1986).
32. Moral, L., Rubio, E. M. & Moya, M. A leishmanin skin test survey in the human population of l'Alacanti region (Spain): Implications for the epidemiology of Leishmania infantum infection in southern Europe. Trans. R. Soc. Trop. Med. Hyg. 96, 129-132 (2002).
33. Sacks, D. L., Lai, S. L., Shrivastava, S. N., Blackwell, J. & Neva, F. A. An analysis of T cell responsiveness in Indian kala-azar. J. Immunol. 138, 908-913 (1987).
34. Ghalib, H. W. et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J. Clin. Invest. 92, 324-329 (1993).
35. Nylen, S. et al. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J. Exp. Med. 204, 805-817 (2007).
36. Cerf, B. J. et al. Malnutrition as a risk factor for severe visceral leishmaniasis. J. Infect. Dis. 156, 1030-1033 (1987).
37. Murray, H. W. Kala-azar as an AIDS-related opportunistic infection. AIDS Patient Care STDs 13, 459-465 (1999).
38. Alvar, J. et al. Leishmania and human immunodeficiency virus coinfection: The first 10 years. Clin. Microbiol. Rev. 10, 298-319 (1997).
39. Carvalho, E. M. et al. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J. Infect. Dis. 165, 535-540 (1992).
40. Karplus, T. M. et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect. Immun. 70, 6919-6925 (2002).
41. Blackwell, J. M., Mohamed, H. S. & Ibrahim, M. E. Genetics and visceral leishmaniasis in the Sudan: Seeking a link. Trends Parasitol. 20, 268-274 (2004).
42. Davies, C. R., Kaye, P., Croft, S. L. & Sundar, S. Leishmaniasis: New approaches to disease control. BMJ 326, 377-382 (2003).
43. Ashford, D. A. et al. Studies on control of visceral leishmaniasis: Impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am. J. Trop. Med. Hyg. 59, 53-57 (1998).
44. Palatnik-de-Sousa, C. B. et al. Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil. Am. J. Trop. Med. Hyg. 65, 510-517 (2001).
45. Reithinger, R. & Davies, C. R. Canine leishmaniasis: Novel strategies for control. Trends Parasitol. 18, 289-290 (2002).
46. Tesh, R. B. Control of zoonotic visceral leishmaniasis: Is it time to change strategies? Am. J. Trop. Med. Hyg. 52, 287-292 (1995).
47. Alvar, J. et al. Canine leishmaniasis: Clinical, parasitological and entomological follow-up after chemotherapy. Ann. Trop. Med. Parasitol. 88, 371-378 (1994).
48. Gavgani, A. S., Hodjati, M. H., Mohite, H. & Davies, C. R. Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: A matched-cluster randomised trial. Lancet 360, 374-379 (2002).
49. Kaul, S. M., Sharma, R. S., Dey, K. P., Rai, R. N. & Verghese, T. Impact of DDT indoor residual spraying on Phlebotomus argentipes in a kala-azar endemic village in eastern Uttar Pradesh. Bull. World Health Organ. 72, 79-81 (1994).
50. Singh, R., Das, R. K. & Sharma, S. K. Resistance of sandflies to DDT in Kala-azar endemic districts of Bihar, India. Bull. World Health Organ. 79, 793 (2001).
51. Hassan, M. M., Elraba'a, F. M., Ward, R. D., Maingon, R. D. & Elnaiem, D. A. Detection of high rates of in-village transmission of Leishmania donovani in eastern Sudan. Acta Trop. 92, 77-82 (2004).
52. Bern, C. et al. Factors associated with visceral leishmaniasis in Nepal: Bed-net use is strongly protective. Am. J. Trop. Med. Hyg. 63, 184-188 (2000).
53. Bern, C. et al. Risk factors for kala-azar in Bangladesh. Emerg. Infect. Dis. 11, 655-662 (2005).
54. Ritmeijer, K. et al. Evaluation of a mass distribution programme for fine-mesh impregnated bednets against visceral leishmaniasis in eastern Sudan. Trop. Med. Int. Health 12, 404-414 (2007).
55. Reyburn, H., Ashford, R., Mohsen, M., Hewitt, S. & Rowland, M. A randomized controlled trial of insecticide-treated bednets and chaddars or top sheets, and residual spraying of interior rooms for the prevention of cutaneous leishmaniasis in Kabul, Afghanistan. Trans. R. Soc. Trop. Med. Hyg. 94, 361-366 (2000).
56. Kroeger, A., Avila, E. V. & Morison, L. Insecticide impregnated curtains to control domestic transmission of cutaneous leishmaniasis in Venezuela: Cluster randomised trial. BMJ 325, 810-813 (2002).
57. Collin, S. et al. Conflict and kala-azar: Determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin. Infect. Dis. 38, 612-619 (2004).
58. Guerin, P. J. et al. Visceral leishmaniasis: Current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis. 2, 494-501 (2002).
59. Boelaert, M. et al. A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. Am. J. Trop. Med. Hyg. 70, 72-77 (2004).
60. Sundar, S. Diagnosis of kala-azar - an important stride. J. Assoc. Physicians India 51, 753-755 (2003).
61. Zijlstra, E. E. et al. Kala-azar: A comparative study of parasitological methods and the direct agglutination test in diagnosis. Trans. R. Soc. Trop. Med. Hyg. 86, 505-507 (1992).
62. Siddig, M., Ghalib, H., Shillington, D. C. & Petersen, E. A. Visceral leishmaniasis in the Sudan: Comparative parasitological methods of diagnosis. Trans. R. Soc. Trop. Med. Hyg. 82, 66-68 (1988).
63. Young, S. Kala-azar in Pi-Hsien District, Kiangsu Province, China. II. Findings in films of spleen and liver puncture juice and some other observations in kala-azar. J. Shanghai Sci. Inst. 4, 265-272 (1939).
64. Ho, E. A., Soong, T. H. & Li, Y. Comparative merits of sternum, spleen and liver punctures in the study of human leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 41, 629-636 (1948).
65. Babiker, Z. O., Davidson, R., Mazinda, C., Kipngetich, S. & Ritmeijer, K. Utility of lymph node aspiration in the diagnosis of visceral leishmaniasis in Sudan. Am. J. Trop. Med. Hyg. 76, 689-693 (2007).
66. Kager, P. A. & Rees, P. H. Splenic aspiration. Review of the literature. Trop. Geogr. Med. 35, 111-124 (1983).
67. Reithinger, R. & Dujardin, J. C. Molecular diagnosis of leishmaniasis: current status and future applications. J. Clin. Microbiol. 45 21-25 (2007).
68. Kumar, R., Pai, K., Pathak, K. & Sundar, S. Enzyme-linked immunosorbent assay for recombinant K39 antigen in diagnosis and prognosis of Indian visceral leishmaniasis. Clin. Diagn. Lab. Immunol. 8, 1220-1224 (2001).
69. Braz, R. F. et al. The sensitivity and specificity of Leishmania chagasi recombinant K39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection. Am. J. Trop. Med. Hyg. 67, 344-348 (2002).
70. De Almeida Silva, L. et al. Immunologic tests in patients after clinical cure of visceral leishmaniasis. Am. J. Trop. Med. Hyg. 75, 739-743 (2006).
71. Hailu, A. Pre- and post-treatment antibody levels in visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 84, 673-675 (1990).
72. Koirala, S., Karki, P., Das, M. L., Parija, S. C. & Karki, B. M. Epidemiological study of kala-azar by direct agglutination test in two rural communities of eastern Nepal. Trop. Med. Int. Health 9 533-537 (2004).
73. Schenkel, K. et al. Visceral leishmaniasis in southeastern Nepal: a cross-sectional survey on Leishmania donovani infection and its risk factors. Trop. Med. Int. Health 11, 1792-1799 (2006).
74. Sundar, S. et al. Serological diagnosis of Indian visceral leishmaniasis: Direct agglutination test versus rK39 strip test. Trans. R. Soc. Trop. Med. Hyg. 100, 533-537 (2006).
75. Sundar, S. et al. Rapid, noninvasive diagnosis of visceral leishmaniasis in India: Comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J. Clin. Microbiol. 44, 251-253 (2006).
76. Ibrahim, M. E. et al. Kala-azar in a high transmission focus: An ethnic and geographic dimension. Am. J. Trop. Med. Hyg. 61, 941-944 (1999).
77. Ho, M., Leeuwenburg, J., Mbugua, G., Wamachi, A. & Voller, A. An enzyme-linked immunosorbent assay (ELISA) for field diagnosis of visceral leishmaniasis. Am. J. Trop. Med. Hyg. 32, 943-946 (1983).
78. Iqbal, J. et al. Imported visceral leishmaniasis: Diagnostic dilemmas and comparative analysis of three assays. J. Clin. Microbiol. 40, 475-479 (2002).
79. Sinha, R. & Sehgal, S. Comparative evaluation of serological tests in Indian kala-azar. J. Trop. Med. Hyg. 97, 333-340 (1994).
80. Sreenivas, G. et al. Diagnosis of visceral leishmaniasis: comparative potential of amastigote antigen, recombinant antigen and PCR. Br. J. Biomed. Sci. 59, 218-222 (2002).
81. Harith, A. E. et al. A simple and economical direct agglutination test for serodiagnosis and sero-epidemiological studies of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 80, 583-536 (1986).
82. Harith, A. E. et al. Evaluation of a newly developed direct agglutination test (DAT) for serodiagnosis and sero-epidemiological studies of visceral leishmaniasis: Comparison with IFAT and ELISA. Trans. R. Soc. Trop. Med. Hyg. 81, 603-606 (1987).
83. Chappuis, F., Rijal, S., Soto, A., Menten, J. & Boelaert, M. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ 333, 723 (2006).
84. Boelaert, M. et al. Multi-centre evaluation of repeatability and reproducibility of the direct agglutination test for visceral leishmaniasis. Trop. Med. Int. Health 4, 31-37 (1999).
85. Jacquet, D. et al. Comparative evaluation of freeze-dried and liquid antigens in the direct agglutination test for serodiagnosis of visceral leishmaniasis (ITMA-DAT/VL). Trop. Med. Int. Health 11 1777-1784 (2006).
86. Meredith, S. E. et al. Leish-KIT, a stable direct agglutination test based on freeze-dried antigen for serodiagnosis of visceral leishmaniasis. J. Clin. Microbiol. 33, 1742-1745 (1995).
87. Schoone, G. J. et al. A fast agglutination screening test (FAST) for the detection of anti-Leishmania antibodies. Trans. R. Soc. Trop. Med. Hyg. 95, 400-401 (2001).
88. Hailu, A. et al. Field evaluation of a fast anti-Leishmania antibody detection assay in Ethiopia. Trans. R. Soc. Trop. Med. Hyg. 100, 48-52 (2006).
89. Silva, E. S. et al. Application of direct agglutination test (DAT) and fast agglutination screening test (FAST) for sero-diagnosis of visceral leishmaniasis in endemic area of Minas Gerais, Brazil. Kinetoplastid Biol. Dis. 4, 4 (2005).
90. Burns, J. M., Jr et al. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc. Natl Acad. Sci. USA 90, 775-779 (1993).
91. Zijlstra, E. E. et al. rK39 enzyme-linked immunosorbent assay for diagnosis of Leishmania donovani infection. Clin. Diagn. Lab. Immunol. 5, 717-720 (1998).
92. Zijlstra, E. E. et al. Diagnosing visceral leishmaniasis with the recombinant K39 strip test: Experience from the Sudan. Trop. Med. Int. Health 6, 108-113 (2001).
93. Ozensoy, S. et al. Serodiagnosis and epidemiology of visceral leishmaniasis in Turkey. Am. J. Trop. Med. Hyg. 59, 363-369 (1998).
94. Maalej, I. A. et al. Comparative evaluation of ELISAs based on ten recombinant or purified Leishmania antigens for the serodiagnosis of Mediterranean visceral leishmaniasis. Am. J. Trop. Med. Hyg. 68, 312-320 (2003).
95. Kurkjian, K. M. et al. Application of an improved method for the recombinant k39 enzyme-linked immunosorbent assay to detect visceral leishmaniasis disease and infection in Bangladesh. Clin. Diagn. Lab. Immunol. 12, 1410-1415 (2005).
96. Singh, S., Gilman-Sachs, A., Chang, K. P. & Reed, S. G. Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis. J. Parasitol. 81, 1000-1003 (1995).
97. Ou, J. O. et al. Serodiagnosis of Asian leishmaniasis with a recombinant antigen from the repetitive domain of a Leishmania kinesin. Trans. R. Soc. Trop. Med. Hyg. 88, 543-545 (1994).
98. Badaro, R. et al. rK39: A cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J. Infect. Dis. 173, 758-761 (1996).
99. Chappuis, F. et al. Field validity, reproducibility and feasibility of diagnostic tests for visceral leishmaniasis in rural Nepal. Trop. Med. Int. Health 11, 31-40 (2006).
100. Sundar, S. et al. Comparative evaluation of parasitology and serological tests in the diagnosis of visceral leishmaniasis in India: A phase III diagnostic accuracy study. Trop. Med. Int. Health 12 284-289 (2007).
101. Ritmeijer, K. et al. Evaluation of a new recombinant K39 rapid diagnostic test for Sudanese visceral leishmaniasis. Am. J. Trop. Med. Hyg. 74, 76-80 (2006).
102. Veeken, H., Ritmeijer, K., Seaman, J. & Davidson, R. Comparison of an rK39 dipstick rapid test with direct agglutination test and splenic aspiration for the diagnosis of kala-azar in Sudan. Trop. Med. Int. Health 8, 164-167 (2003).
103. Diro, E. et al. Field evaluation of FD-DAT, rk-39 dipstick and KATEX (urine latex agglutination) for diagnosis of visceral leishmaniasis in northwest Ethiopia. Trans. R. Soc. Trop. Med. Hyg. (in the press).
104. Boelaert, M. et al. Diagnostic tests for kala-azar: A multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East-Africa and the Indian subcontinent. Trans. R. Soc. Trop. Med. Hyg. (in the press).
105. Chappuis, F. et al. Diagnostic accuracy of two rK39 antigen-based dipsticks and the formal gel test for rapid diagnosis of visceral leishmaniasis in northeastern Uganda. J. Clin. Microbiol. 43 5973-5977 (2005).
106. Attar, Z. J. et al. Latex agglutination test for the detection of urinary antigens in visceral leishmaniasis. Acta Trop. 78, 11-16 (2001).
107. Sarkari, B., Chance, M. & Hommel, M. Antigenuria in visceral leishmaniasis: Detection and partial characterisation of a carbohydrate antigen. Acta Trop. 82, 339-348 (2002).
108. Rijal, S. et al. Evaluation of a urinary antigen-based latex agglutination test in the diagnosis of kala-azar in eastern Nepal. Trop. Med. Int. Health 9, 724-729 (2004).
109. Sundar, S., Agrawal, S., Pai, K., Chance, M. & Hommel, M. Detection of leishmanial antigen in the urine of patients with visceral leishmaniasis by a latex agglutination test. Am. J. Trop. Med. Hyg. 73, 269-271 (2005).
110. El-Safi, S. H. et al. Field evaluation of latex agglutination test for detecting urinary antigens in visceral leishmaniasis in Sudan. East Mediterr. Health J. 9, 844-855 (2003).
111. Veeken, H., Ritmeijer, K., Seaman, J. & Davidson, R. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop. Med. Int. Health 5, 312-317 (2000).
112. Moore, E. et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull. World Health Organ. 79, 388-393 (2001).
113. Ritmeijer, K. et al. Ethiopian visceral leishmaniasis: Generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans. R. Soc. Trop. Med. Hyg. 95 668-672 (2001).
114. Seaman, J., Mercer, A. J., Sondorp, H. E. & Herwaldt, B. L. Epidemic visceral leishmaniasis in southern Sudan: Treatment of severely debilitated patients under wartime conditions and with limited resources. Ann. Intern. Med. 124, 664-672 (1996).
115. Sundar, S. et al. Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian epidemic. Clin. Infect. Dis. 31, 1104-1107 (2000).
116. Yamey, G. & Torreele, E. The world's most neglected diseases. BMJ 325, 176-177 (2002).
117. Gradoni, L., Gramiccia, M. & Scalone, A. Visceral leishmaniasis treatment. Italy. Emerg. Infect. Dis. 9, 1617-1620 (2003).
118. Bern, C. et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin. Infect. Dis. 43, 917-924 (2006).
119. Berman, J. Miltefosine to treat leishmaniasis. Expert Opin. Pharmacother. 6, 1381-1388 (2005).
120. Bhattacharya, S. K. et al. Phase IV trial of miltefosine in the treatment of Indian visceral leishmaniasis. J. Infect. Dis. 196 591-598 (2007).
121. Ritmeijer, K. et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin. Infect. Dis. 43, 357-364 (2006).
122. Sundar, S. & Murray, H.W. Availability of miltefosine for the treatment of kala-azar in India. Bull. World Health Organ. 83, 394-395 (2005).
123. Perez-Victoria, F. J. et al. Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist. Update 9, 26-39 (2006).
124. Thakur, C.P. Socio-economics of visceral leishmaniasis in Bihar (India). Trans. R. Soc. Trop. Med. Hyg. 94, 156-157 (2000).
125. den Boer, M. & Davidson, R. N. Treatment options for visceral leishmaniasis. Expert Rev. Anti Infect. Ther. 4, 187-197 (2006).
126. Chunge, C. N., Owate, J., Pamba, H. O. & Donno, L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans. R. Soc. Trop. Med. Hyg. 84, 221-225 (1990).
127. Jha, T. K. et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 316, 1200-1205 (1998).
128. Sundar, S. et al. Injectable paromomycin for visceral leishmaniasis in India. N. Engl. J. Med. 356, 2571-2581 (2007).
129. Sherwood, J. A. et al. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin. Infect. Dis. 19, 1034-1039 (1994).
130. Jha, T. K. et al. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am. J. Trop. Med. Hyg. 73, 1005-1011 (2005).
131. Dietze, R. et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am. J. Trop. Med. Hyg. 65, 685-689 (2001).
132. Wasunna, M. K. et al. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am. J. Trop. Med. Hyg. 73, 871-876 (2005).
133. Bryceson, A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop. Med. Int. Health 6, 928-934 (2001).
134. Seaman, J. et al. Epidemic visceral leishmaniasis in Sudan: A randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J. Infect. Dis. 168, 715-720 (1993).
135. Thakur, C. P. et al. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 94, 429-431 (2000).
136. Melaku, Y. et al. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: A retrospective comparison with 30-day sodium stibogluconate monotherapy. Am. J. Trop. Med. Hyg. 77, 89-94 (2007).
137. Kedzierski, L., Zhu, Y. & Handman, E. Leishmania vaccines: progress and problems. Parasitology 133, S87-S112 (2006).
138. Amaral, V. F. et al. Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease. Mem. Inst. Oswaldo Cruz 97, 1041-1048 (2002).
139. Uzonna, J. E., Spath, G. F., Beverley, S. M. & Scott, P. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J. Immunol. 172, 3793-3797 (2004).
140. Alexander, J., Coombs, G. H. & Mottram, J. C. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J. Immunol. 161, 6794-6801 (1998).
141. Saha, S. et al. Immune responses in kala-azar. Indian J. Med. Res. 123, 245-266 (2006).
142. Ivens, A. C. et al. The genome of the kinetoplastid parasite, Leishmania major. Science 309, 436-442 (2005).
143. Nadim, A., Javadian, E., Tahvildar-Bidruni, G. & Ghorbani, M. Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull. Soc. Pathol. Exot. Filiales 76, 377-383 (1983).
144. Greenblatt, C. L. Cutaneous leishmaniasis: The prospects for a killed vaccine. Parasitol. Today 4, 53-54 (1988).
145. Khalil, E. A. et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: A randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356, 1565-1569 (2000).
146. Khamesipour, A. et al. Leishmanization: Use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 23, 3642-3648 (2005).
147. Velez, I.D. et al. Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Trans. R. Soc. Trop. Med. Hyg. 99, 593-598 (2005).
148. Modabber, F., Campos-Neto, A. & Reed, S. in New Generation Vaccines (eds Levine, M. et al.) (Marcel Dekker, New York, 2004).
149. Skeiky, Y. A. et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20, 3292-3303 (2002).
150. Reed, S. G., Coler, R. N. & Campos-Neto, A. Development of a leishmaniasis vaccine: The importance of MPL. Expert Rev. Vaccines 2, 239-252 (2003).
151. Musa, A. M. et al. Safety, immunogenicity and possible efficacy of immunochemotherapy of persistent post kala-azar dermal leishmaniasis. Sudanese J. Dermatol. 3, 63-72 (2005).
152. Moreno, J., Canavate, C., Chamizo, C., Laguna, F. & Alvar, J. HIV- Leishmania infantum co-infection: Humoral and cellular immune responses to the parasite after chemotherapy. Trans. R. Soc. Trop. Med. Hyg. 94, 328-332 (2000).
153. Deniau, M., Canavate, C., Faraut-Gambarelli, F. & Marty, P. The biological diagnosis of leishmaniasis in HIV-infected patients. Ann. Trop. Med. Parasitol. 97 (Suppl. 1), 115-133 (2003).
154. Rosenthal, E. et al. HIV and Leishmania coinfection: A review of 91 cases with focus on atypical locations of Leishmania. Clin. Infect. Dis. 31, 1093-1095 (2000).
155. Hailu, A. & Berhe, N. The performance of direct agglutination tests (DAT) in the diagnosis of visceral leishmaniasis among Ethiopian patients with HIV coinfection. Ann. Trop. Med. Parasitol. 96 25-30 (2002).
156. Riera, C. et al. Evaluation of a latex agglutination test (KAtex) for detection of Leishmania antigen in urine of patients with HIV-Leishmania coinfection: Value in diagnosis and post-treatment follow-up. Eur. J. Clin. Microbiol. Infect. Dis. 23, 899-904 (2004).
157. Sindermann, H., Engel, K. R., Fischer, C. & Bommer, W. Oral miltefosine for leishmaniasis in immunocompromised patients: Compassionate use in 39 patients with HIV infection. Clin. Infect. Dis. 39, 1520-1523 (2004).
158. Davidson, R. N. et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: A multi-centre trial. O. J. Med. 87, 75-81 (1994).
159. Laguna, F. et al. Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 13, 1063-1069 (1999).
160. Pasquau, F. et al. Leishmaniasis as an opportunistic infection in HIV-infected patients: Determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region. Eur. J. Clin. Microbiol. Infect. Dis. 24, 411-418 (2005).
161. Lopez-Velez, R. et al. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am. J. Trop. Med. Hyg. 58, 436-443 (1998).
162. Mira, J. A. et al. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am. J. Trop. Med. Hyg. 70, 298-301 (2004).
163. Fernandez Cotarelo, M. J. et al. Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 37, 973-977 (2003).
164. de la Rosa, R. et al. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 32 633-635 (2001).
165. Lopez-Velez, R. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV. Ann. Trop. Med. Parasitol. 97 (Suppl. 1), 143-147 (2003).
166. Rosenthal, E. et al. Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy. AIDS 15, 1184-1185 (2001).
167. Desjeux, P. Disease Watch Focus: Leishmaniasis. Nature Rev. Microbiol. 2, 692-693 (2004).
168. Handman, E. Leishmaniasis: Current status of vaccine development. Clin. Microbiol. Rev. 14, 229-243 (2001).